CACNA1C

Voltage-dependent L-type calcium channel subunit alpha-1C · Q13936 · CACNA1C on Sugi Atlas →

137,431 patent compounds predicted against CACNA1C, 94,712 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116362	0.45	11/20
Nisoldipine (SCHEMBL39779)	1.00	10/20
Nisoldipine (SCHEMBL39780)	1.00	10/20
Efonidipine (SCHEMBL49637)	0.59	10/20
Efonidipine (SCHEMBL49638)	0.59	10/20
Nitrendipine (SCHEMBL38972)	0.91	9/20
(R)-Nitrendipine (SCHEMBL38973)	0.91	9/20
(S)-Nitrendipine (SCHEMBL120983)	0.91	9/20
Nimodipine (SCHEMBL34041)	0.82	9/20
(S)-Nimodipine (SCHEMBL34042)	0.82	9/20
Cilnidipine (SCHEMBL25550)	1.00	8/20
Cilnidipine (SCHEMBL25551)	1.00	8/20
Mibefradil (SCHEMBL39551)	1.00	8/20
Mibefradil (SCHEMBL120810)	0.99	8/20
SCHEMBL25549	0.83	8/20
Nifedipine (SCHEMBL3968)	1.00	6/20
SCHEMBL133106	1.00	5/20
Aranidipine (SCHEMBL49910)	0.80	5/20
Aranidipine (SCHEMBL49911)	0.80	5/20
Darodipine (SCHEMBL44696)	0.69	5/20

Clinical trials — most relevant to CACNA1C by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination	PHASE4	UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning	PHASE2/PHASE3	WITHDRAWN
Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy	PHASE3	COMPLETED
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease	PHASE2	COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome	PHASE1/PHASE2	NOT_YET_RECRUITING
4-Aminopyridine in Episodic Ataxia Type 2	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients	PHASE2	WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients	PHASE2	WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain	PHASE2	COMPLETED
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis	PHASE2	COMPLETED
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
Physiologic Effects of Topiramate on Cognition	PHASE1	COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development	nan	RECRUITING
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism	nan	COMPLETED
Evaluation of A Clinical Diagnostic Test for CRDS	nan	RECRUITING
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia	nan	COMPLETED
International CRDS Registry	nan	RECRUITING
Verapamil in Supraclavicular Brachial Plexus Block	nan	UNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics	nan	UNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY)	nan	COMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study	nan	UNKNOWN
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors	nan	UNKNOWN
Sodium Channel Splicing in Heart Failure Trial	nan	COMPLETED
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13)	nan	NOT_YET_RECRUITING
Presternal Magnesium With Bupivacain Versus Bupivacain Only for Postoperative Pain Relief in Open Heart Surgery	nan	COMPLETED
The Prevalence of RYR1-related Disease	nan	NOT_YET_RECRUITING
Postoperative Pain Alleviation in Open Heart Surgery	nan	COMPLETED
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Pharmacogenetics and Cardiovascular Events	nan	COMPLETED
A Causal Role for Voltage-gated Cav1.2 Calcium Channels in Mediating 5G FR1 Effects on Sleep-associated Brain Health in Humans	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CACNA1C binder may also engage these)

Protein	Name	Similarity
O73700	—	1.000	O73700 →
CACNA1D	Voltage-dependent L-type calcium channel subunit alpha-1D	1.000	landscape →
P22002	—	1.000	P22002 →
P15381	—	1.000	P15381 →
P27732	—	1.000	P27732 →
Q01815	—	1.000	Q01815 →
O35505	—	1.000	O35505 →
Q02789	—	1.000	Q02789 →
Q99244	—	0.999	Q99244 →
O57483	—	0.999	O57483 →
Q99246	—	0.998	Q99246 →
P54282	—	0.998	P54282 →
P97445	—	0.997	P97445 →
C9D7C2	—	0.997	C9D7C2 →
P07293	—	0.996	P07293 →
CACNA1A	Voltage-dependent P/Q-type calcium channel subunit alpha-1A	0.994	landscape →
Q25452	—	0.994	Q25452 →
Q05152	—	0.994	Q05152 →
P56698	—	0.993	P56698 →
Q07652	—	0.993	Q07652 →
Q61290	—	0.993	Q61290 →
P22316	—	0.993	P22316 →
Q28644	—	0.992	Q28644 →
Q02485	—	0.992	Q02485 →
Q02294	—	0.992	Q02294 →
Q62205	—	0.992	Q62205 →
CACNA1S	Voltage-dependent L-type calcium channel subunit alpha-1S	0.991	landscape →
P91645	—	0.991	P91645 →
CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1B	0.990	landscape →
O55017	—	0.990	O55017 →